Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.

Etzioni R, Gulati R, Falcon S, Penson DF.

Med Decis Making. 2008 May-Jun;28(3):323-31. doi: 10.1177/0272989X07312719. Epub 2008 Mar 4.

PMID:
18319508
2.

Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.

Telesca D, Etzioni R, Gulati R.

Biometrics. 2008 Mar;64(1):10-9. Epub 2007 May 14.

PMID:
17501937
3.
4.

Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.

Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT.

J Natl Cancer Inst. 2006 Aug 16;98(16):1134-41.

5.

The effectiveness of screening for prostate cancer: a nested case-control study.

Concato J, Wells CK, Horwitz RI, Penson D, Fincke G, Berlowitz DR, Froehlich G, Blake D, Vickers MA, Gehr GA, Raheb NH, Sullivan G, Peduzzi P.

Arch Intern Med. 2006 Jan 9;166(1):38-43.

PMID:
16401808
6.

A population model of prostate cancer incidence.

Tsodikov A, Szabo A, Wegelin J.

Stat Med. 2006 Aug 30;25(16):2846-66.

PMID:
16397859
7.

Does current evidence justify prostate cancer screening in Europe?

Martin RM, Smith GD, Donovan J.

Nat Clin Pract Oncol. 2005 Nov;2(11):538-9. No abstract available.

8.

What is the value of screening for prostate cancer in the US?

Albertsen PC.

Nat Clin Pract Oncol. 2005 Nov;2(11):536-7. No abstract available.

PMID:
16270077
9.

Effect of screening and adjuvant therapy on mortality from breast cancer.

Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ; Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators.

N Engl J Med. 2005 Oct 27;353(17):1784-92.

10.

Revisiting my personal decision about prostate-specific antigen testing in 2005.

Barry MJ.

BJU Int. 2005 Nov;96(7):954-6. No abstract available.

11.

Radical prostatectomy versus watchful waiting in early prostate cancer.

Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO, Bratell S, Spångberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, Norlén BJ, Johansson JE; Scandinavian Prostate Cancer Group Study No. 4.

N Engl J Med. 2005 May 12;352(19):1977-84.

12.

Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.

Pinsky PF, Andriole GL, Kramer BS, Hayes RB, Prorok PC, Gohagan JK; Prostate, Lung, Colorectal and Ovarian Project Team.

J Urol. 2005 Mar;173(3):746-50; discussion 750-1.

PMID:
15711261
13.

Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999.

Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF.

Urology. 2004 Dec;64(6):1171-6.

PMID:
15596192
14.

An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States.

Shaw PA, Etzioni R, Zeliadt SB, Mariotto A, Karnofski K, Penson DF, Weiss NS, Feuer EJ.

Am J Epidemiol. 2004 Dec 1;160(11):1059-69.

15.

Cancer trends in the United States--a view from Europe.

Quinn MJ.

J Natl Cancer Inst. 2003 Sep 3;95(17):1258-61. Review. No abstract available.

16.

National practice patterns and time trends in androgen ablation for localized prostate cancer.

Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR.

J Natl Cancer Inst. 2003 Jul 2;95(13):981-9.

17.

The influence of finasteride on the development of prostate cancer.

Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr.

N Engl J Med. 2003 Jul 17;349(3):215-24. Epub 2003 Jun 24.

18.

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ.

J Natl Cancer Inst. 2003 Jun 18;95(12):868-78.

19.

Challenges to cancer control by screening.

Pollak MN, Foulkes WD.

Nat Rev Cancer. 2003 Apr;3(4):297-303. Review.

PMID:
12671668
20.
Items per page

Supplemental Content

Write to the Help Desk